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Summary: An immunoradiometric assay is described for the determination of human anti-idiotypic anti-B72.3 IgG.
The latter is formed in ovarian cancer patients after treatment with the murine monoclonal antibody B72.3, which
is directed against the tumour-associated glycoprotein 72 (TAG-72). A gel coupled with Fc-specific anti-human
IgG antibodies is used as a solid phase for the extraction of serum IgG. The anti-B72.3 IgG is then specifically
detected by incubation with radiolabelled B72.3 detector antibodies. Calibration standards were prepared from
serum obtained from a patient repeatedly treated with B72.3 antibodies. The concentration of anti-idiotypic anti-
B72.3 antibodies was expressed as TAG-72-like arb.units/1. The assay performed with two 60-minute incubation
steps is characterized by a high sensitivity (detection limit: 3 Χ 103 arb.units/1) and precision (coefficients of
variation: intra-assay = 6.4% and 5.8% at 80 X 103 arb. units/1 and 217 Χ 103 arb.units/1, inter-assay = 8.7% and
7.1% at 91 X 103 arb.units/1 and 212 Χ 103 arb.units/1) and a good linearity of dilution (recovery after dilution
between 99% and 107%). The assay is more specific than previously described methods; no interference was
observed by TAG-72 up to 3.3 Χ 107 arb.units/1. Also, non-specific human anti-mouse antibodies did not cross-
react up to 34.8 mg/1. The test may be modified for detection of anti-idiotypic antibodies, which are formed after
treatment with other monoclonal antibodies.
Introduction
A novel therapeutic approach to the treatment of ma-
lignant neoplasms is the application of unconjugated
monoclonal antibodies directed against a tumour-asso-
ciated antigen expressed on the tumour cells. An indi-
rect mechanism is thought to be involved in the bene-
ficial effect observed in cancer patients after treatment
with monoclonal antibodies (1). According to the idio-
typic network hypothesis proposed by Jerne (2), injec-
tion of a monoclonal antibody specific for a tumour-
associated antigen induces the formation of anti-idio-
typic antibodies which subsequently may induce the
formation of anti^anti-idiotypic antibodies, which in
return recognize the same epitope on the tumour-asso-
ciated antigen as on the original antibody. These anti-
anti-idiotypic antibodies as well as nti-idiotype re-
active T-cells (3) may kill the tumour-cells bearing
the tumour-associated antigen by a direct mechanism.
Induction of such a humoral idiotypic cascade has
been shown after the in vivo application of various
monoclonal antibodies (4—7), and the formation of
anti-idiotypic antibodies has been favorably correlated
with the response of the patients (1, 6, 8, 9).
In most studies, anti-idiotypic antibodies have been
measured with an "indirect" assay, in which the anti-
idiotypic antibodies are captured by the immobilized
original antibody, then detected by incubation with la-
belled anti-human immunoglobulin G (IgG) or immuno-
globulin M antibodies (4, 6, 10). Alternatively, in the
direct "sandwich"-assay, the original antibody is used as
both capture and detector antibody (9—12). In both
types of assay the original antibody bound to a solid
phase is incubated with whole serum. Thus, for serum
samples containing the original tumour antigen, interfer-
ence is to be expected, leading to falsely low or falsely
high assay results (7, 10, 13, 14).
Recently, in a clinical trial evaluating the effect of
repeated infusion of low doses of the murine monoclo-
nal antibody B72.3 in ovarian cancer patients, the
formation of anti-idiotypic anti-B72.3 antibodies was
shown (9). The B72.3 antibody defines the tumour-
associated glycoprotein 72 (TAG-72), a surface antigen
expressed in the majority of human epithelial cancers
(15, 16), which is also released into the serum (17,
18). Thus, the anti-idiotypic antibody concentration
could be assessed only in samples with low TAG-72
concentrations because the TAG-72 present in patient
serum cross-reacted with the "sandwich" assay used
in this study (19). To allow the determination of hu-
man anti-idiotypic anti-B72.3 antibodies, even in the
presence of TAG-72, we developed an immunoradio-
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metric assay which is not affected by TAG-72. This
assay uses a gel coupled with Fc-specific anti-human
IgG antibodies to extract the serum IgG, before spe-
cific detection of the anti-idiotypic anti-B72.3 antibod-
ies by radiolabelled B72.3 detector antibodies.
Materials and Methods
Patients and serum samples
Serum samples were obtained from ovarian cancer patients (stage
III-IV FIGO) who had received one or more infusions of 1 mg of
the B72.3 antibody (Oncoscint; Eurocetus, Frankfurt, Germany).
Samples drawn before antibody treatment served as control. Addi-
tional control samples were obtained from four patients during the
in vitro fertilization cycle. Samples with elevated non-specific hu-
man anti-mouse antibody concentrations were obtained from four
patients treated with radiolabelled F(abf>2 fragments of the murine
antibody OC125 (IMACIS-2; Isotopen Diagnostik CIS, Dreieich,
Germany) for the purpose of radioimmunodetection (8), and from
one patient treated with the murine antibody B43.13 (Biomira, Ed-
monton, Canada) for the purpose of photodynamic therapy (20).
All samples were aliquoted and stored at -20 °C until analysis.
The procedures followed in this study were in accordance with the
standards of the ethical committee of our faculty.
Coupling of anti-human IgG antibodies
to hydrazide gel
Fc-specific anti-human IgG antibodies were coupled to hydrazide
gel (Avidchrom Hydrazide Gel F; Sysmex, Hamburg, Germany)
according to the procedure described by Radparvar et al. (21). For
buffer exchange 2 ml of a Fc-specific goat anti-human IgG anti-
body solution (2.4 g/1; Sigma, Deisenhofen, Germany) were con-
centrated with a Centricon-30 concentrator (Amicon, Witten, Ger-
many) to an end volume of 0.04 ml and refilled with 2 ml of cou-
pling buffer (0.05 mol/1 sodium acetate, pH 5.0). Then 0.2 ml of a
sodium /weta-periodate solution (0.1 mol/1) was added. After incu-
bation for 20 minutes at room temperature, the oxidized antibody
sample was applied to a 2 ml hydrazide gel column equilibrated
with 16ml coupling buffer. After a 15-minute incubation at room
temperature, the column was washed with 16ml coupling buffer
and 16 ml phosphate-buffered saline (0.01 mol/1 sodium phosphate,
0.0027 mol/1 potassium chloride, 0.137 mol/1 sodium chloride, pH
7.4) to elute the uncoupled antibodies. Then the gel was removed
from the column and suspended in phosphate-buffered saline (1 ml
gel in 9 ml buffer).
The maximum binding capacity of the gel was determined by incu-
bating 0.1 ml gel with 0.5 ml of human IgG (reagent grade, Sigma,
Deisenhofen, Germany; 0.2 g/1) dissolved in assay buffer (1 ml/1
Tween-20 in phosphate-buffered saline) for one hour at room tem-
perature with continuous shaking. At the end of the incubation, the
gel was sedimented and washed three times with 3 ml assay buffer.
The bound human IgG was then eluted by incubation with 0.3 ml
glycine buffer (0.1 mol/1 glycine-HCl, pH 2.7). After centrifugation
the amount of IgG recovered in the supernatant was quantitated by
measuring the absorbance at 280 nm.
Standard material
Serum drawn from an ovarian cancer patient two weeks after the
fourth B72.3 infusion was used as standard material. A nominal
value of 6.1 X 106 arbitrary units/1 (arb.units/1) of anti-idiotypic
anti-B72.3 antibodies was assigned to this standard material, ac-
cording to the value measured with the "sandwich assay" described
below. Serum drawn from 5 healthy women was pooled and diluted
1/200 with assay buffer to give the zero standard. Dilutions of the
standard material were made in zero standard after 1/200 predilu-
tion of the standard material with assay buffer to give a range
of standards from 0 to 3.05 103 arb.units/1. The standards were
aliquoted and stored at -20 °C until used.
Immunoradiometr ic assay (IRMA) for determination
of human anti-idiotypic anti-B72.3 IgG
Standard assay protocol: 0.4 ml of the anti-human IgG gel suspen-
sion prepared as described above was pipetted into conical polysty-
rene test tubes and centrifuged at 3500 g for 10 minutes. After
aspiration of the supernatant, 0.2 ml of standards prepared as de-
scribed above or 0.2 ml of test serum diluted 1/200 in assay buffer
were added and incubated at room temperature for one hour with
continuous shaking. At the end of the incubation the gel was sedi-
mented by centrifugation and washed three times with 3 ml assay
buffer. Then 0.2 ml of a solution containing I25l-labelled B72.3
detector antibodies (provided as tracer in the B72.3- M-K-S kit;
Sorin Biomedica, Düsseldorf, Germany) diluted 2-fold with assay
buffer were added to each tube. To block non-specific binding of
the B72.3 detector antibodies to human anti-iso/allotypic anti-
B72.3 antibodies, the solution was supplemented with non-specific
murine IgG: 0.008 ml of murine IgG (reagent grade; Sigma,
Deisenhofen, Germany; 20 g/1) were added to 0.232 ml of antibody
solution. After incubation for one hour at room temperature with
continuous shaking the gel again was sedimented and washed three
times with 3 ml assay buffer. The radioactivity bound to the gel
was measured.
To evaluate the effect of increasing the amount of gel, in some
experiments the test volume in the first incubation step was raised
from 0.12 ml (0.1 ml sample + 0.02 ml gel) to 1.2 ml (1.0 ml
sample + 0.2 ml gel), followed by a second incubation with 0.5
ml labelled B72.3 detector antibodies.
"Sandwich assay" for determination of anti-idiotypic
anti-B72.3 antibodies
For comparison, anti-idiotypic anti-B72.3 antibodies were
mined with a homologous "sandwich assay" using the B72.3-M^
K-S kit (Sorin Biomedica, Düsseldorf, Germany) with slight modi-
fications. In this commercially available test for TAG-72, antl·
B72.3 antibodies can cause a falsely high TAG-72-like assay re-
sponse. In samples with low real TAG-72 concentrations the results
of the B72.3-M-K-S reflect the concentration of the anti-B72.3 an-
tibodies (19). To block anti-iso/allotypic anti-B72.3 antibodies,
0.008 ml of a solution of non-specific murine IgG (20 g/1) was
added to 0.232 ml of sample. The concentration of the anti-idio-
typic anti-B72.3 antibodies was expressed as TAG-72-like arbi-
trary units/1.
Determination of real tumour-associated
glycoprotein 72
The real TAG-72 concentrations of the serum samples were mea-
sured with the ELSA CA 72-4 (Isotopen Diagnostik CIS, Dreieich,
Germany) as described elsewhere (19). To eliminate interference
by anti-B72.3 antibodies, samples were heated before the TAG-72
determination as described previously, to extract interfering immu-
noglobulins (19).
Determination of human anti-mouse antibodies
Non-specific human (anti-iso/allotypic) anti-mouse antibodies
(HAMAs) were determined with the HAMA-ELISA-medäc
(Medac, Hamburg, Germany) using mouse IgG as both capture and
detector antigen. In patients not treated with murine antibodies the
concentration of human anti-mouse antibodies ranged from
0-0.2 mg/1.
Determination of human serum immunoglobulin G
Human serum IgG was determined by radial immunodififusion on
LC-Partigen IgG plates (Behring, Marburg, Germany).
Evaluation of analytical performance
The within-assay precision was calculated from replicate determin-
ations of a sample in a single assay. Between-assay precision was
calculated from the values measured for a sample in consecutive
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Fig. 1 Variation of incubation time. When the contact time of the
zero standard (o) and the 1.53 X 103 arb.units/1 standard (D) with
the solid phase-bound anti-human IgG antibodies was increased
from 30 to 180 minutes (first incubation step), this was followed
by 60 minutes incubation with the B72.3 detector antibodies. When
the contact time with the B72.3 detector antibodies (second incuba-
tion step) was increased from 30 to 180 minutes, the zero standard
(o) and the 1.53 X JO3 arb.units/1 standard (O) were preincubated
with the solid phase bound anti-human IgG antibodies for 60 min-
utes. Except for variation of the incubation time, the IRMA was
carried out according to the standard protocol.
assays. The detection limit was assessed by calculating the con-
centration which corresponds in the standard curve to the mean
signal of 10 replicates of the zero standard + 3 standard devia-
tions. For recovery studies, samples were spiked with a standard
pool and the resulting concentration of anti-idiotypic antibodies
was measured. For assessment of the linearity of dilution, the
anti-idiotypic antibody concentrations measured in samples seri-
ally diluted with zero standard (after 1/200 predilution with assay
buffer) were compared with the expected values. To examine the
effect of elevated concentrations of serum IgG and TAG-72 on
assay results, a standard solution with a known concentration of
anti-idiotypic antibodies was measured after addition of increas-
ing amounts of human serum IgG and TAG-72, respectively. As
a source of TAG-72 we used a mucin prepared from bovine
submaxillary glands (Sigma, Deisenhofen, Germany). For com-
parison of methods, linear regression analysis was performed by
the method of Bablok et al. (22).
Results
Development of an immunoradiometric assay
(IRMA) for determination of human anti-idio-
typic anti-B72.3 IgG
As shown in figure 1, for the zero standard as well as the
1.53 Χ 103 arb.units/1 standard, only small differences in
the resulting test signal were observed when the incuba-
tion time of the two incubation steps of the IRMA was
increased from 60 to 180 minutes. Thus, for the standard
assay protocol we used an incubation time of one hour
for each incubation.
The binding capacity for human IgG of two different gel
preparations coupled with anti-human IgG antibodies
was 37 and 42 μg per 0.04 ml gel. Because of the high
IgG concentration in the serum samples (3 to 25 g/1),
we diluted the standard material and serum samples
1/200 with assay buffer before applying the standard as-
say protocol, to guarantee that serum IgG is completely
bound to the solid phase. When the volume of gel and
o.oo 0.05 0.10 0.15
Gel volume [ml]
0.20
Fig. 2 Variation of gel volume. The signal (D; radioactivity bound
in the presence of the 0.76 Χ 103 arb.units/1 standard), the noise
(o; radioactivity bound in the presence of the zero standard) and
the ratio between signal and noise (^) were determined when the
test volume in the first incubation step was raised from 0.12 ml
(0.1 ml standard + 0.02 ml gel) to 1.2 ml (1.0 ml standard + 0.2
ml gel), followed by a second incubation with 0.5 ml labelled
B72.3 detector antibodies. Except for variation of the incubation
volumes the IRMA was carried out according to the standard proto-
col.
sample in the first incubation step was increased (from
0.02 ml gel and 0.1 ml sample up to 0.2 ml gel and 1.0
ml sample) both the signal (bound radioactivity due to
the presence of anti-idiotypic antibodies) of the 0.76
Χ 103 arb.units/1 standard and the noise (bound radioac-
tivity in the absence of anti-idiotypic antibodies) of the
zero standard continued to increase. However, the sig-
nal-to-noise ratio also continuously increased (fig. 2).
Thus, subsequent assays were performed with 0.04 ml
gel and 0.2 ml of standards or serum samples prediluted
1/200 with assay buffer.
We used serum from an ovarian cancer patient treated
repeatedly with B72.3 antibodies as standard material.
Whereas the heterologous TAG-72 assay detected no
real TAG-72 in this standard material, the homologous
"sandwich assay" showed apparent TAG-72 value of 6.1
Χ 106 arb.units/1, obviously due to the activity of human
anti-idiotypic anti-B72.3 antibodies present in the se-
rum. Thus, an arbitrary anti-idiotypic anti-B72.3 anti-
o.o 1.0 2.0 3.0 4.0
Anti-idiotypic antibodies [10s a rb. u nits/I]
Fig. 3 Dilution curve of standard material. The standard pool was
diluted with zero standard after 1/200 predilution with assay buffer.
The IRMA was carried out according to the standard protocol.
240 Reinsberg et ai.: Determination of anti-idiotypic anti-B72.3 antibodies in the presence of tumour-associated glycoprotein 72
body concentration of 6.1 X 106 TAG-72-like units/1
(arb.units/1) was assigned to the standard material. No
human anti-mouse antibodies and anti-idiotypic anti-
B72.3 antibodies were detected in the serum pool used
as zero standard. Standards ranging from 0 to 3.05
X 103 arb.units/1 were prepared from the standard mate-
rial by dilution with zero standard. As shown in figure
3 the standard curve measured with the IRMA was lin-
ear up to a concentration of 3.05 Χ 103 arb.units/1.
Analytical performance
The minimal detectable concentration assessed on the
basis of 10 replicate measurements of the zero calibrator
was lower than 0.015 Χ 103 arb.units/1, corresponding
to detection limit in the undiluted serum of 3 X 103
arb.units/1. Within-assay precision, tested with two sam-
ples with mean anti-idiotypic antibody concentrations of
80 and 217 Χ 103 arb.units/1, revealed coefficients of
variation of 6.4% and 5.8% (n = 20)· The between-as-
say precision, calculated from values measured in 20
consecutive runs for two samples with mean anti-idio-
typic antibody concentrations of 91 and 212 X 103
arb.units/1, revealed coefficients of variation of 8.7%
and 7.1%. The linearity of dilution was checked for
three serum samples with elevated anti-idiotypic anti-
body concentrations (153, 277, 290 Χ 103 arb.units/1)
Tab. 1 Assay performance of the IRMA standard protocol.
a) Linearity of dilution. Serum samples were serially diluted with
zero standard after 1/200 predilution with assay buffer.
Sample identification Dilution Anti-idiotypic anti-B72.3 antibodies
(103 arb.units/1)
Recovery (%)a
10117
10618
8107
1/1
1/2
1/4
1/1
1/2
1/4
1/1
1/2
1/4
Measured
153
76
39
277
144
74
290
148
76
Expected
77
38
139
69
145
73
99
102
104
107
102
105
b) Recovery. 0.01 ml of the standard pool diluted 1/200 with assay
buffer was added to 0.29 ml serum prediluted 1/200 with assay
buffer and the resulting anti-idiotypic antibody concentrations
were measured.
Sample
identification
930b
931b
932b
933b
600C
11225d
Anti-idiotypic anti-B72.3 antibodies
Endogenous
14
4
<3
<3
<3
<3
Added
193
193
193
193
193
193
(103 arb.units/1)
Expected
207
197
193
193
193
193
Recovered
208
192
159
187
188
183
Recovery (%)a
101
98
82
97
97
95
c) Interferences by non-specific human anti-mouse antibodies
(HAMA). Serum samples with elevated human anti-mouse anti-
body concentration were measured directly (after 1/200 predilution
with assay buffer) or after addition of 0.01 ml of the standard pool
(diluted 1/200 with assay buffer) to 0.29 ml of the prediluted se-
rum.
Sample
identification
8027e
22788°
7754e
6437e
11055f
HAMA
(mg/1)
2.1
5.1
8.3
34.8
12.3
Anti-idiotypic anti-B72.3 antibodies (103 arb.units/1)
Endogenous Added
<3
8
6
<3
<3
203
203
203
—
Expected
211
209
203
Recovered
_
219
210
201
Recovery (%)a
_
104
100
99
a
 Recovery = (anti-idiotypic antibody concentration measured/ex-
pected) X 100
b
 Obtained from four in vitro fertilization patients
c
 TAG-72 concentration = 709 Χ 103 arb.units/1
d
 TAG-72 concentration = 6940 Χ 103 arb.units/1
e
 Obtained from four ovarian cancer patients treated with OC125
fragments
f
 Obtained from an ovarian cancer patient treated with B43.13 an-
tibodies · ί
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Fig. 4 Recovery of anti-idiotypic anti-B72.3 antibodies in the
presence of increasing serum IgG concentration. A 0.76 Χ 103 arb.
units/I standard solution prediluted 1/200 with assay buffer was
supplemented with increasing amounts of human IgG and mea-
sured with the IRMA according to the standard protocol.
obtained from three patients. The concentrations mea-
sured after 2- and 4-fold dilutions of the 1/200 predi-
luted serum samples were only slightly different from
the expected values (tab. la).
Interferences
As shown in figure 4 the results of the IRMA for a 0.76
X 103 arb.units/1 standard solution were not affected by
addition of increasing amounts of human serum IgG up
to an IgG concentration of 175 mg/l (corresponding to
a IgG concentration of 35 g/1 in the undiluted serum
sample). However, in the presence of higher IgG con-
centrations the assay results were considerably reduced.
Furthermore, six serum samples from different patients
with serum IgG concentrations from 11 to 18 g/1,
showed almost complete recovery of added anti-idio-
typic antibodies (tab. Ib), confirming that the different
IgG concentrations of the samples have no effect on the
assay results.
As shown in table Ib, the two samples with elevated
TAG-72 concentrations (sample identification: 600 and
11225) showed almost complete recovery of anti-idio-
typic antibodies, indicating that the TAG-72 antigen has
no effect upon the results of the IRMA. In the same way,
increasing the TAG-72 concentration up to 3.3 Χ ΙΟ**
arb.units/1, by addition of bovine mucin containing
TAG-72-like immunoreactive material, has virtually Ho
effect on the results measured in a 1.15 Χ 103 arb.units/1
standard solution (apparent concentration of the standard
in the presence of 3.3 Χ 107 arb.units/1 TAG-72 = 1.19
Χ 103 arb.units/1).
The apparent anti-idiotypic anti-B72.3 antibody concen-
tration measured in five serum samples from patients
treated with the murine antibodies OC125 (four patients)
and B43.13 (one patient), with non-specific human anti-
mouse antibody concentrations ranging from 2.1 to 34.8
mg/l, did not exceed 8 Χ 103 arb.units/1. Also anti-idio-
typic antibodies added to three of the samples were reco-
vered almost completely (tab. Ic).
Cl in ica l evaluation
As shown in table 2, in the samples obtained from 16
ovarian cancer patients before treatment with B72.3 an-
tibodies, the concentration of anti-idiotypic anti-B72.3
antibodies did not exceed 12 Χ 103 arb.units/1. This is
in accordance with the results measured in the control
samples (tab. Ib). However, after infusion of B72.3 anti-
bodies, 9 patients showed grossly elevated anti-idiotypic
antibody concentrations ranging from 204 to 2164
Χ 103 arb.units/1; in 4 patients values were slightly ele-
vated ranging from 27 to 66 Χ 103 arb.units/1; anti-idio-
typic antibodies were undetectable in only 3 patients.
The human anti-mouse antibodies concentration of the
samples drawn after antibody treatment ranged from
<0.1 to 4.2 mg/l.
Figure 5 shows the time course of the concentration of
the anti-idiotypic anti-B72.3 antibodies measured with
the IRMA and with the "sandwich" assay, respectively,
in serum samples drawn from an ovarian cancer patient
treated three times with B72.3 antibodies. Three weeks
after the third B72.3 infusion, the IRMA detected an
increase of the anti-idiotypic antibody concentration up
to 587 Χ 103 arb.units/1 followed by a decrease to
20xl03 arb.units/1 five months later. Also the values
measured with the "sandwich" assay rose three weeks
after the third infusion to 443 Χ 103 arb.units/1 followed
by an initial decrease to 187 Χ 103 arb.units/1 ten weeks
later. However, the values then again rose up to 260
X 103 arb.units/1, obviously due to the continous
increase of the TAG-72 concentration measured in the
same period.
Tab. 2 Anti-idiotypic anti-B72.3 antibody concentration in pa-
tients treated with the B72.3 antibody. Serum samples drawn from
16 patients before and after B72.3 infusion were measured with
the IRMA according to the standard protocol.
Patients
EH
KE
RC
WU
HI
VM
MU
BB
SR
AM
BI
BM
FR
MH
SE
TL
Number
of infusions
2
2
6
3
1
3
3
4
1
3
4
3
3
6
3
1
Anti-idiotypic
anti-B72.3 antibodies
(103 arb.units/1)
before
treatment
4
<3
<3
<3
<3
<3
<3
<3
<3
<3
<3
<3
<3
12
<3
6
after last
infusion
<3
<3
<3
27
34
43
66
204
420
470
526
587
793
815
1572
2164
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Fig. 5 Typical time course of the formation of anti-idiotypic
anti-B72.3 antibodies measured with the IRMA (Π) and the
"sandwich" assay (o), respectively, during repeated treatment
with Β72.3 antibodies in an ovarian cancer patient with increas-
ing TAG-72 serum concentration (+)· Arrows indicate the time
of OC125 infusions.
0.1 1 10 100
TAG-72-like activity (IRMA) [105 arb.units/l]
Fig. 6 Comparison of the results measured with the IRMA and
the "sandwich" assay, in serum samples obtained from patients
after treatment with B72.3 antibodies with low (O) and elevated
(o) TAG-72 concentrations. The regression line was calculated
for the values measured in the samples with low TAG-72 con-
centration.
In figure 6 the values measured with the IRMA are
compared with the results of the "sandwich" assay.
For 10 samples with low TAG-72 concentrations there
was a good correlation between both rests (r = 0.981;
regression line y = 1.1 χ + 7.6). For 9 samples with
TAG-72 concentrations ranging from 189 to 5490
Χ 103 arb.units/l the values measured with the "sand-
wich" assay were considerably higher than those from
the IRMA.
Discussion
The advantage of the IRMA described here is that the
human serum IgG is first selectively extracted by ad-
sorption to solid phase coupled anti-human IgG antibod-
ies. Thus, serum components which may react with the
B72.3 detector antibodies can be removed by a washing
step and possible interference can be excluded. The data
also confirm that very high TAG-72 concentrations have
no effect upon the results of the IRMA, whereas the
"sandwich" assay gave falsely high values, due to cross-
reaction with TAG-72.
In most assays for detection of anti-idiotypic antibod-
ies described in various papers, the murine antibody
bearing the original idiotype is coupled to a solid
phase and incubated with the serum samples (4, 6,
9-12, 14). Thus, interfering serum components in-
cluding circulating antigen can react with the immobi-
lized antibody leading to falsely low or falsely high
assay results (7, 10, 13, 14). In patients treated with
the anti-TAG-72 antibody B72.3 or the anti-CA-125
antibody OC125, which are directed against antigens
which can be present in serum in very high concentra-
tions, interference by elevated antigen concentrations
in the patient serum can be a problem.
In order to eliminate interference by circulating anti-
gen in the determination of anti-idiotypic anti-B72.3
antibodies, Ferroni et al. (14) proposed that the TAG-
72 be removed from patient serum by adsorption to
the solid phase coupled anti-TAG-72 antibody CC49
which recognizes a separate epitope on the TAG-72
antigen (23). This is a time-consuming procedure and
an additional antibody is required which specifically
binds the antigen but does not react with the anti-
idiotypic antibodies. A more simple method has been
described by Moseley et al. (13). For determination
of human antibodies formed against the anti-CA-125
antibody OC125 they used microtitre wells coated
with protein A to extract the immunoglobulins from
serum. The anti-idiotypic anti-OC125 antibodies bound
to protein A are subsequently detected by incubation
with radiolabelled F(ab)2 fragments of the OC125. This
may be a simple assay, but F(ab)2 fragments of the
original antibody must be available to avoid binding
of detector antibodies to protein A on the solid phase.
Further problems arise from the high concentration of
non-specific IgG present in human serum samples.
Because of the limited binding capacity of the protein
A on the solid phase (10 μg per well), serum samples
must be prediluted 1/100 for correct determination,
leading to a decline of sensitivity (13). In the IRMA
described here the sensitivity is also limited by the
binding capacity of the solid phase for human serum
IgG. However, this problem can be compensated partly
by increasing the amount of gel used in the first
incubation step. On the other hand, the density of
antibodies coupled to the hydrazide gel can be sub-
stantially enhanced by increasing the amount of anti-
body reacted (21). This may be a further way of
increasing the binding capacity of the'solid phase in
order to achieve an improved analytical sensitivity.
A farther advantage of the IRMA is that, because of
the specificity of the capture antibodies used, only anti-
idiotypic antibodies of the IgG class are detected. The
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assay may be adapted for the determination of anti-idio-
typic antibodies of the IgM class by using a gel coupled
with anti-human-IgM capture antibodies.
The validity of the IRMA is confirmed by the data ob-
tained for serum samples from patients treated with
B72.3 antibodies. In samples drawn before antibody
treatment, the IRMA detected no or only marginally ele-
vated anti-idiotypic anti-B72.3 IgG, thereby indicating
that the assay is highly specific. Obviously, non-specific
interference, as observed with the "indirect" assay for-
mat (10), does not affect the IRMA. Also, no false posi-
tive values were found in samples with high concentra-
tions of non-specific human anti-mouse antibodies up to
34.8 mg/1. Thus, the amount of murine IgG added to the
detector antibodies of the IRMA is sufficient to block
the human anti-mouse antibodies activity of the samples
drawn after B72.3 treatment which did not exceed 4.2
mg/1.
In 81% of the posttreatment samples we found ele-
vated anti-idiotypic anti-B72.3 IgG concentrations, in-
dicating that the assay is highly sensitive. The time
course of the appearance of anti-idiotypic antibodies
during antibody treatment shows a good correlation
between the time of antibody infusion and the appear-
ance of anti-idiotypic antibodies. The validity of the
results is further confirmed by the coincidence with
the values measured with the "sandwich" assay for
samples with low TAG-72 concentration. However,
because the "sandwich" assay detects all classes of
anti-idiotypic antibodies, the good agreement between
both assays suggests that in the samples compared,
the concentration of the anti-idiotypic IgG antibodies
is considerably higher than that of the anti-idiotypic
antibodies of the other immunoglobulin classes. This
may be due to the fact that only one of these samples
was drawn within the first weeks following to the
first antibody infusion. As reported by Courtenay-Luck
et al. (4), the immune response to repeated antibody
infusions is mainly of the IgG class.
Because the only specific reagent required for the IRMA
is the labelled original antibody, the test may be modi-
fied to detect anti-idiotypic antibodies, which were
formed after treatment with other monoclonal antibod-
ies. At present we have performed preliminary experi-
ments which suggest that this assay design also can be
used for determination of human anti-idiotypic antibod-
ies directed against the anti-CA-125 antibodies B43.13
and OC125.
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